298 related articles for article (PubMed ID: 29367052)
1. Construction and optimization of pH-sensitive nanoparticle delivery system containing PLGA and UCCs-2 for targeted treatment of Helicobacter pylori.
Luo M; Jia YY; Jing ZW; Li C; Zhou SY; Mei QB; Zhang BL
Colloids Surf B Biointerfaces; 2018 Apr; 164():11-19. PubMed ID: 29367052
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori.
Jing ZW; Jia YY; Wan N; Luo M; Huan ML; Kang TB; Zhou SY; Zhang BL
Biomaterials; 2016 Apr; 84():276-285. PubMed ID: 26851392
[TBL] [Abstract][Full Text] [Related]
3. Anti-Helicobacterpylori effectiveness and targeted delivery performance of amoxicillin-UCCs-2/TPP nanoparticles based on ureido-modified chitosan derivative.
Jing ZW; Luo M; Jia YY; Li C; Zhou SY; Mei QB; Zhang BL
Int J Biol Macromol; 2018 Aug; 115():367-374. PubMed ID: 29660462
[TBL] [Abstract][Full Text] [Related]
4. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori.
Arif M; Dong QJ; Raja MA; Zeenat S; Chi Z; Liu CG
Mater Sci Eng C Mater Biol Appl; 2018 Feb; 83():17-24. PubMed ID: 29208276
[TBL] [Abstract][Full Text] [Related]
5. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori.
Jain SK; Haider T; Kumar A; Jain A
AAPS PharmSciTech; 2016 Oct; 17(5):1131-40. PubMed ID: 26566630
[TBL] [Abstract][Full Text] [Related]
6. Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori.
Lotfipour F; Valizadeh H; Milani M; Bahrami N; Ghotaslou R
Drug Res (Stuttg); 2016 Jan; 66(1):41-5. PubMed ID: 25919643
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles incorporated in pH-sensitive hydrogels as amoxicillin delivery for eradication of Helicobacter pylori.
Chang CH; Lin YH; Yeh CL; Chen YC; Chiou SF; Hsu YM; Chen YS; Wang CC
Biomacromolecules; 2010 Jan; 11(1):133-42. PubMed ID: 19924885
[TBL] [Abstract][Full Text] [Related]
8. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin.
Chen H; Xie LQ; Qin J; Jia Y; Cai X; Nan W; Yang W; Lv F; Zhang QQ
Colloids Surf B Biointerfaces; 2016 Feb; 138():1-9. PubMed ID: 26638176
[TBL] [Abstract][Full Text] [Related]
9. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-modified PLGA nanoparticles tagged with 5TR1 aptamer for in vivo tumor-targeted drug delivery.
Taghavi S; Ramezani M; Alibolandi M; Abnous K; Taghdisi SM
Cancer Lett; 2017 Aug; 400():1-8. PubMed ID: 28412238
[TBL] [Abstract][Full Text] [Related]
11. Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection.
Tan Z; Liu W; Liu H; Li C; Zhang Y; Meng X; Tang T; Xi T; Xing Y
Eur J Pharm Biopharm; 2017 Feb; 111():33-43. PubMed ID: 27865932
[TBL] [Abstract][Full Text] [Related]
12. CS/PAA@TPGS/PLGA nanoparticles with intracellular pH-sensitive sequential release for delivering drug to the nucleus of MDR cells.
Wang YY; Zhang DD; Kong YY; Shao LL; Zhang FY; Gao Y; Mu X; Wang J; Li HF; Yu SQ; Xu Q
Colloids Surf B Biointerfaces; 2016 Sep; 145():716-727. PubMed ID: 27289313
[TBL] [Abstract][Full Text] [Related]
13. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases.
Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM
J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705
[TBL] [Abstract][Full Text] [Related]
14. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.
Wang H; Liu J; Tao S; Chai G; Wang J; Hu FQ; Yuan H
Int J Nanomedicine; 2015; 10():5671-85. PubMed ID: 26388691
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells.
Wang H; Agarwal P; Zhao S; Xu RX; Yu J; Lu X; He X
Biomaterials; 2015 Dec; 72():74-89. PubMed ID: 26344365
[TBL] [Abstract][Full Text] [Related]
16. Surface-functionalized, pH-responsive poly(lactic-co-glycolic acid)-based microparticles for intranasal vaccine delivery: Effect of surface modification with chitosan and mannan.
Li Z; Xiong F; He J; Dai X; Wang G
Eur J Pharm Biopharm; 2016 Dec; 109():24-34. PubMed ID: 27569030
[TBL] [Abstract][Full Text] [Related]
17. Genipin-cross-linked fucose-chitosan/heparin nanoparticles for the eradication of Helicobacter pylori.
Lin YH; Tsai SC; Lai CH; Lee CH; He ZS; Tseng GC
Biomaterials; 2013 Jun; 34(18):4466-79. PubMed ID: 23499480
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation.
Pandit J; Sultana Y; Aqil M
Artif Cells Nanomed Biotechnol; 2017 Nov; 45(7):1397-1407. PubMed ID: 27855494
[TBL] [Abstract][Full Text] [Related]
19. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
20. Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori.
Ramteke S; Ganesh N; Bhattacharya S; Jain NK
J Drug Target; 2009 Apr; 17(3):225-34. PubMed ID: 19241256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
